Citigroup’s Eterna Therapeutics ERNA Stock Holding History

Citigroup’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-408	Closed	-$27.3K	–	5721
2025 Q1	$27.3K	Buy	+408	New	+$50.3K	﹤0.01%	5025
2024 Q4	–	Hold	0	–	–	–	5790
2024 Q3	–	Hold	0	–	–	–	5600
2024 Q2	–	Hold	0	–	–	–	5489
2024 Q1	–	Hold	0	–	–	–	5531
2023 Q4	–	Hold	0	–	–	–	5608
2023 Q3	–	Hold	0	–	–	–	5556
2023 Q2	–	Hold	0	–	–	–	5487
2023 Q1	–	Hold	0	–	–	–	5324
2022 Q4	–	Hold	0	–	–	–	5669
2022 Q3	–	Hold	0	–	–	–	5962
2022 Q2	–	Hold	0	–	–	–	6013
2022 Q1	–	Sell	-1	Closed	-$19K	–	5808
2021 Q4	$39K	Buy	+1	New	+$54.4K	﹤0.01%	5185
2021 Q3	–	Hold	0	–	–	–	4940
2021 Q2	–	Hold	0	–	–	–	5154
2015 Q1	–	Hold	0	–	–	–	7246
2014 Q4	–	Hold	0	–	–	–	7153
2014 Q3	–	Hold	0	–	-$1K	–	7118
2014 Q2	–	Hold	0	–	–	–	6901

Other funds holding ERNA

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth Miami, Florida $72.2B AUM 27.85% 1-Year Est. Return

Sippican Capital Advisors Boston, Massachusetts $150M AUM 15.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup's ERNA Position: Q2 2025 in Review

Citigroup sold out of Eterna Therapeutics (ERNA) in Q2 2025, closing a stake of 408 shares — an estimated $27.3K sold.

Citigroup first reported a position in ERNA in Q4 2021 and held it in 2 quarters. The position peaked at $39K in Q4 2021. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2025.

Citigroup reported no remaining Eterna Therapeutics position as of Q2 2025 after selling out during the quarter.
Citigroup sold 408 Eterna Therapeutics shares in Q2 2025, an estimated $27.3K.
Citigroup first reported a position in Eterna Therapeutics in Q4 2021 and held it in 2 quarters.
Citigroup's Eterna Therapeutics position peaked at $39K in Q4 2021.
9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2025.

Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.